GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Current Deferred Taxes Liabilities

Vertex Pharmaceuticals (BSP:VRTX34) Current Deferred Taxes Liabilities : R$0 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Vertex Pharmaceuticals's current deferred tax liabilities for the quarter that ended in Sep. 2024 was R$0 Mil.

Vertex Pharmaceuticals Current Deferred Taxes Liabilities Historical Data

The historical data trend for Vertex Pharmaceuticals's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Current Deferred Taxes Liabilities Chart

Vertex Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vertex Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vertex Pharmaceuticals Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Current Deferred Taxes Liabilities
Comparable Companies
REGN ALNY BNTX BGNE MRNA SMMT UTHR PCVX BMRN INCY ASX:CSL XKRX:207940 XBRU:UCB XBRU:ARGX XKRX:068270 OCSE:GMAB XKRX:196170 SHSE:603392 SRPT INSM
Traded in Other Exchanges
VRTX:USA VRTX:Mexico 1VRTX:Italy 0QZU:UK VX1:Germany VX1:Germany VX1:Germany VX1:Germany VRTX:Austria
Address
50 Northern Avenue, Boston, MA, USA, 02210
Website
https://www.vrtx.com
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Headlines

No Headlines